Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Alessandra Narcisi, Carlo Giovanni Carrera et al.|Journal of Dermatological Treatment|2024Cited by 21
Mycosis fungoides: disease evolution of the "lion queen" revisited.Pietro Quaglino, Mg Bernengo, Nicola Pimpinelli et al.|PubMed|2012Cited by 12
Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER studyClaudio Bonifati, Giuseppe Argenziano, Serena Lembo et al.|Journal of the European Academy of Dermatology and Venereology|2024Cited by 10
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyC. Bonifati, Antonio Costanzo, G. Argenziano et al.|Journal of Dermatological Treatment|2026Cited by 1
Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER studyClaudio Bonifati, Antonio Costanzo, Giuseppe Argenziano et al.|Open MIND|2026Cited by 0